Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Blood Sampling
2.3. The DOAC-Stop Procedure
2.4. Diluted Thrombin Time
2.5. Anti-Xa Activity Assay
2.6. Liquid Chromatography Tandem Mass Spectrometry (LC-MS)
2.7. Lupus Anticoagulants
2.8. Statistical Analysis
3. Results
3.1. The dTT and Anti-Xa Tests Do Not Correlate with LC-MS in Samples from Patients with Lupus
3.2. dTT and Anti-Xa Strongly Correlate with LA Ratio
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Adcock, D.; Gosselin, R. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb. Res. 2015, 136, 7–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Makam, R.C.P.; Hoaglin, D.C.; McManus, D.D.; Wang, V.; Gore, J.M.; Spencer, F.A.; Pradhan, R.; Tran, H.; Yu, H.; Goldberg, R.J. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS ONE 2018, 13, e0197583. [Google Scholar] [CrossRef] [PubMed]
- Cuker, A.; Siegal, D.; Crowther, M.; Garcia, D.A. Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants. J. Am. Coll. Cardiol. 2014, 64, 1128–1139. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brinkman, H.J.M. Global assays and the management of oral anticoagulation. Thromb. J. 2015, 13, 1–14. [Google Scholar] [CrossRef] [Green Version]
- Stangier, J.; Feuring, M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul. Fibrinolysis 2012, 23, 138–143. [Google Scholar] [CrossRef] [PubMed]
- Tripodi, A. The Laboratory and the New Oral Anticoagulants. Clin. Chem. 2013, 59, 353–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Devreese, K.M.J.; Groot, P.G.; Laat, B.; Erkan, D.; Favaloro, E.J.; Mackie, I.; Martinuzzo, M.; Ortel, T.L.; Pengo, V.; Rand, J.H.; et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 2020, 18, 2828–2839. [Google Scholar] [CrossRef] [PubMed]
- Slavik, L.; Lukes, J.; Friedecky, D.; Zhanelova, M.; Nemcova, M.; Ulehlova, J.; Prochazkova, J.; Hlusi, A.; Palova, M.; Vaclavik, J. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays. Clin. Lab. 2018, 64, 1611–1621. [Google Scholar] [CrossRef] [PubMed]
- Slavik, L.; Jacova, J.; Friedecky, D.; Ulehlova, J.; Tauber, Z.; Prochazkova, J.; Hlusi, A.; Palova, M. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban. Clin. Appl. Thromb. 2019, 25, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Zar, J.H. Biostatistical Analysis, 4th ed.; Pearson Education: Noida, India, 1999. [Google Scholar]
- Exner, T.; Rigano, J.; Favaloro, E.J. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int. J. Lab. Hematol. 2020, 42, 41–48. [Google Scholar] [CrossRef]
- Farkh, C.; Ellouze, S.; Gounelle, L.; Houari, M.S.; Duchemin, J.; Proulle, V.; Fontenay, M.; Delavenne, X.; Jourdi, G. A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter. Front. Med. 2021, 8, 683357. [Google Scholar] [CrossRef]
- Favresse, J.; Lardinois, B.; Sabor, L.; Devalet, B.; Vandepapeliere, J.; Braibant, M.; Lessire, S.; Chatelain, B.; Jacqmin, H.; Douxfils, J.; et al. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests. TH Open 2018, 2, e202–e209. [Google Scholar] [CrossRef] [Green Version]
- Favaloro, E.J.; Gilmore, G.; Bonar, R.; Dean, E.; Arunachalam, S.; Mohammed, S.; Baker, R. Laboratory testing for activated protein C resistance: Rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. Clin. Chem. Lab. Med. 2020, 58, 1322–1331. [Google Scholar] [CrossRef] [PubMed]
- Monteyne, T.; De Kesel, P.; Devreese, K.M. Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays. Thromb. Res. 2020, 192, 96–99. [Google Scholar] [CrossRef] [PubMed]
- De Kesel, P.M.; Devreese, K.M.J. Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing—Review of the literature and evaluation on spiked and patient samples. J. Thromb. Haemost. 2020, 18, 2003–2017. [Google Scholar] [CrossRef] [PubMed]
- Frans, G.; Meeus, P.; Bailleul, E. Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon. J. Thromb. Haemost. 2019, 17, 1354–1362. [Google Scholar] [CrossRef] [PubMed]
- Butler, J.; Malan, E.; Chunilal, S.; Tran, H.; Hapgood, G. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb. Haemost. 2013, 110, 308–315. [Google Scholar] [CrossRef] [PubMed]
- Wong, W.H.; Kaur, H.; Tan, C.W.; Lee, L.H.; Ng, H.J. Cross-interference of rivaroxaban and enoxaparin on Berichrom anti-Xa heparin and Biophen direct Xa inhibitor assays. Int. J. Lab. Hematol. 2018, 40, e63–e65. [Google Scholar] [CrossRef] [PubMed]
- Favaloro, E.J.; Lippi, G. Interference of direct oral anticoagulants in haemostasis assays: High potential for diagnostic false positives and false negatives. High. Speed Blood Transfus. Equip. 2017, 15, 491–494. [Google Scholar]
Test | Median | Min | Max | Q1 | Q3 | Distribution |
---|---|---|---|---|---|---|
LA ratio | 1.63 | 1.23 | 5.95 | 1.42 | 2.13 | |
DABI, functional assay | 96.9 | 68.0 | 235.0 | 76.9 | 114.8 | |
DABI, LC-MS | 51.2 | 21.0 | 69.8 | 36.5 | 58.8 | |
RIVA, functional assay | 88.2 | 57.5 | 235.0 | 72.6 | 109.9 | |
RIVA, LC-MS | 83.0 | 31.9 | 107.8 | 49.9 | 92.8 | |
API, functional assay | 106.1 | 70.8 | 235.0 | 91.1 | 115.1 | |
API, LC-MS | 225.4 | 158.3 | 499.3 | 212.0 | 282.6 | |
DABI, functional assay, DOAC-Stop | 58.1 | 42.6 | 213.2 | 48.9 | 68.9 | |
DABI, LC-MS, DOAC-Stop | 0.28 | 0.10 | 2.56 | 0.19 | 0.33 | |
RIVA, functional assay, DOAC-Stop | 55.5 | 43.5 | 218.3 | 48.8 | 77.9 | |
RIVA, LC-MS, DOAC-Stop | 0.72 | 0.10 | 3.81 | 0.37 | 1.16 | |
API, functional assay, DOAC-Stop | 74.0 | 57.8 | 146.6 | 66.9 | 82.3 | |
API, LC-MS, DOAC-Stop | 3.60 | 0.10 | 34.74 | 2.13 | 6.68 | |
Test | Correlation Coefficient | p-Value |
---|---|---|
DABI, functional assay | 0.72 | <0.0001 |
DABI, LC-MS | −0.02 | 0.9057 |
RIVA, functional assay | 0.81 | <0.0001 |
RIVA, LC-MS | −0.20 | 0.2787 |
API, functional assay | 0.49 | 0.0056 |
API, LC-MS | −0.11 | 0.5627 |
DABI, functional assay, DOAC-Stop | 0.84 | <0.0001 |
DABI, LC-MS, DOAC-Stop | 0.02 | 0.9218 |
RIVA, functional assay, DOAC-Stop | 0.91 | <0.0001 |
RIVA, LC-MS, DOAC-Stop | 0.10 | 0.6207 |
API, functional assay, DOAC-Stop | 0.58 | 0.0006 |
API, LC-MS, DOAC-Stop | 0.18 | 0.3215 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Úlehlová, J.; Piskláková, B.; Ivanovová, E.; Procházková, J.; Bradáčová, P.; Kvasnička, A.; Friedecký, D.; Slavík, L. Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients. Diagnostics 2021, 11, 2027. https://doi.org/10.3390/diagnostics11112027
Úlehlová J, Piskláková B, Ivanovová E, Procházková J, Bradáčová P, Kvasnička A, Friedecký D, Slavík L. Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients. Diagnostics. 2021; 11(11):2027. https://doi.org/10.3390/diagnostics11112027
Chicago/Turabian StyleÚlehlová, Jana, Barbora Piskláková, Eliška Ivanovová, Jana Procházková, Pavla Bradáčová, Aleš Kvasnička, David Friedecký, and Luděk Slavík. 2021. "Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients" Diagnostics 11, no. 11: 2027. https://doi.org/10.3390/diagnostics11112027
APA StyleÚlehlová, J., Piskláková, B., Ivanovová, E., Procházková, J., Bradáčová, P., Kvasnička, A., Friedecký, D., & Slavík, L. (2021). Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients. Diagnostics, 11(11), 2027. https://doi.org/10.3390/diagnostics11112027